Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;22(3):293-e82.
doi: 10.1111/j.1365-2982.2009.01442.x. Epub 2009 Dec 21.

Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort

Affiliations

Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort

N Manabe et al. Neurogastroenterol Motil. 2010 Mar.

Abstract

BACKGROUND Abnormalities of colonic motility were reported in relatively small studies of patients with lower functional gastrointestinal disorders (FGID) including irritable bowel syndrome (IBS). The influence of gender and body mass on the observed motor pathophysiology is unclear. We sought to compare colonic transit in patients within different lower FGID subgroups and healthy controls, controlling for gender and BMI, and to determine whether BMI independently influences colonic motility. METHODS We evaluated a scintigraphic gastrointestinal and colonic transit database of 287 lower FGID patients associated with constipation (IBS-C, or functional constipation, n = 118), diarrhoea (IBS-D or functional diarrhoea, n = 139) or mixed bowel function (IBS-M, n = 30) and 170 healthy controls. We measured colon filling at 6 h (CF 6 h), and overall colonic transit at 8, 24 and 48 h. KEY RESULTS Colon filling at 6 h did not differentiate health from FGID. Colonic transit was abnormal at 24 h (GC24 of <1.50 or >3.86) in 29.7% of all lower FGID patients. There was a significant overall association between colonic transit and subject group (healthy controls and FGID subgroups) at 8 (P = 0.01), 24 (P < 0.001) and 48 h (P < 0.001) in particular for those with diarrhoea or constipation at 24 and 48 h (P < 0.05), even after adjusting for age, gender and BMI. In addition, BMI was associated with colonic transit after adjusting for age, gender and subject group. CONCLUSIONS & INFERENCES Abnormal transit is documented non-invasively with scintigraphy in 30% of lower FGID patients; transit measurement may help document pathophysiology and inform selection of therapy in lower FGID.

PubMed Disclaimer

Figures

Figure 1a
Figure 1a
Histograms showing distribution of GC24 for healthy controls and for patients with each lower FGID subtype. The 10th and 90th percentile cut off are defined using the distribution of the healthy control sample for GC24.
Figure 1b
Figure 1b
Histograms showing distribution of GC48 for healthy controls and for patients with each lower FGID subtype. The 10th and 90th percentile cut off are defined using the distribution of the healthy control sample for GC48.
Figure 2
Figure 2
Comparison of colonic GC at 8, 24 and 48 hours in healthy controls and lower FGID patients with different types of bowel dysfunction. *P <0.05; **P <0.01
Figure 3
Figure 3
Comparison of least square means for colonic GC at 8, 24 and 48 hours among 3 groups according to the BMI values. **P <0.01 versus BMI >30 kg/m2; P=0.018 versus BMI >30 kg/m2

Similar articles

Cited by

References

    1. Bharucha AE, Camilleri M, Haydock S, et al. Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans. Gut. 2000;47:667–74. - PMC - PubMed
    1. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology. 2000;118:463–8. - PubMed
    1. Viramontes BE, Camilleri M, McKinzie S, et al. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96:2671–6. - PubMed
    1. Viramontes BE, Malcolm A, Camilleri M, et al. Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am J Physiol Gastrointest Liver Physiol. 2001;281:G1468–76. - PubMed
    1. Delgado-Aros S, Chial HJ, Camilleri M, et al. Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol. 2003;284:G558–66. - PubMed

Publication types